Landon Donovan recently had a hair transplant, leading to noticeable changes in his appearance. The conversation revolves around his confidence and reactions to his new look.
The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.
The user has been using pyrilutamide, topical finasteride, and 15% minoxidil for hair growth for almost 4 years. Despite mixed responses from others, the user reports seeing progress, especially with the addition of pyrilutamide, and plans to continue the regimen.
The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.
Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
Men with hair loss might have lichen planopilaris (LPP), which can mimic androgenetic alopecia, leading to misdiagnosis and ineffective treatment with finasteride or dutasteride. Proper diagnosis, including biopsies, is crucial to distinguish between androgenetic alopecia and conditions like LPP.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
Scalp tension from the occipitalis muscle is theorized to contribute to hair loss, but most believe DHT and genetics are the main causes. Treatments like finasteride and minoxidil are considered more effective than addressing scalp tension.
The conversation humorously discusses hair loss treatments, mentioning a regime of 1mg oral finasteride, 5% topical finasteride, and 1mg kryptonite. It also references the use of minoxidil for hair regrowth.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
The post and conversation discuss the effectiveness of pyrilutamide for hair loss, with comparisons to finasteride and RU58841. Users express skepticism due to failed trials and high costs, with some waiting for more data before trying pyrilutamide.
Zeuss sublingual products for hair loss, including finasteride and a finasteride-free option, are discussed for their potential to reduce side effects through sublingual delivery. The inclusion of copper peptides is noted, but the high price is a concern without more user feedback.
The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.
Musely sells a hair topical solution containing latanoprost, which degrades in 6 weeks, yet they market it as a 3-month supply. Concerns are raised about the product's effectiveness and the company's sales strategy.
The conversation is about hair loss treatments. The user considers using a foam with Saw palmetto, caffeine, and EGCG, but another user suggests just using finasteride.
The conversation discusses using 2% Pyrilutamide from Anagenica for hair loss, as the user did not see results with 1% Pyrilutamide. The user is considering increasing the dosage but is concerned about the cost.
The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.
Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.
A user is experiencing rapid hair loss and has been diagnosed with telogen effluvium by multiple dermatologists, but doubts the diagnosis due to the severity and speed of the hair loss. They are considering various treatments like spironolactone, estradiol, and possibly finasteride, while also exploring the possibility of hormonal imbalances or autoimmune issues.
Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.
A user shared their 12-month progress using 0.5% Pyrilutamide once daily, 0.025% topical finasteride once daily, 5% Minoxidil twice daily, and microneedling 3 times a week. They reported good progress but noted a slowdown in recent months, hoping for thicker hair soon.
People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.
Hair loss treatments, specifically minoxidil (Minoxidil) and finasteride (Fin). The conversation includes comments about non-responders, the possibility of becoming a responder with grapefruit juice, disappointment, and acceptance of baldness.
A 22-year-old male experienced hair loss potentially linked to escitalopram, which stopped after switching to vortioxetine. His depressive symptoms improved with continued treatment.
Hair loss treatment with Pyrilutamide, Minoxidil, and Finasteride showed improvement after 4 months. Shedding reduced, hair feels stronger and healthier, with no side effects.
A user reported visible hair regrowth after using finasteride for almost six months and inquired if results continue improving over time. They also mentioned using finasteride with sulforaphane and experiencing only minor side effects initially.